Abstract 414P
Background
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours originating from the interstitial cells of Cajal and differentiates from other mesenchymal neoplasm by expression of CD117 oncogene. Most GISTs are found in the stomach followed by small bowels. Using NIH risk groups, the low risk GISTs were less frequent and the highest risk group was the commonest one. The main aim of this study was to evaluate demographic data , assess risk groups and study the clinical outcomes among GIST patients attending the Medical Oncology department , Yangon General hospital from 2015 to 2017.
Methods
Retrospective descriptive study.
Results
Among 73 patients, male: female is 2:1. The most common age group was 51-60 years. Regarding tumor site, small intestine was the most common site and the most patients were found to have tumor size between 11 to 20cm. According to TNM staging, 48% of patients were stage III. By using NIH risk stratification, it was found that 84% of patients were in high risk group. Tumour resection was performed in 77.8% and palliative resection was done in 22.2% of patients. CD117 immunostaining was performed in all 73 patients but CD117 expression was found in 69 patients. 4 patients were CD117 negative but CD34 positive. Therapy with imatinib (400–600mg) was given in 73 patients. Among them, 13 patients was occurred loss follow-up and could not assessed due to social and transportation difficulties. Three patients were expired due to disease progression. 57 patients were alive and taken imatinib up to 3 year. We initially assessed with USG and if there was suspected lesion in USG, we did further advanced imaging like CT. Among these patients who took imatinib up to 3 years, 5 patients was found to have recurrence and change to second line therapy. 52 out of 73 patients remained clinically stable and no recurrence up to 3 years. The most common side effect was generalized edema. The other side effects were whitening of skin and rash . 2 patients suffered dyspnea on exertion and assessed with echocardiogram showing reduced ejection fraction. Dose adjustment was done to these patients. 1 patient was found to have liver function derangement.Table:
414P
Tumour Profile | ||
---|---|---|
Tumour site distribution | No | Percentange |
small intestine | 37 | 51 |
Stomach | 17 | 23 |
Colon and rectum | 10 | 14 |
Extra Gastrointestinal Tract | 9 | 12 |
Tumour sizes distribution | ||
< 10 cm | 24 | 33 |
10-20 cm | 41 | 56 |
>20 cm | 8 | 11 |
Tumour stages distribution | ||
Stage I | 9 | 12 |
Stage II | 13 | 18 |
Stage III | 35 | 48 |
Stage IV | 16 | 22 |
NIH risk distribution | ||
Low | 6 | 8 |
Intermediate | 6 | 8 |
High | 61 | 84 |
Conclusions
This study showed most patients presented with larger tumour sizes, high NIH risk and small intestine. Those who received imatinib up to 3 years had low rate of recurrence and well tolerated.
Clinical trial identification
Editorial acknowledgement
It would not have been possible without the guidance of our professors and co-authors who contributed their valuable expertise to the concepts displayed in this abstract.
Legal entity responsible for the study
Medical Oncology, Yangon General Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract